Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share

Core Viewpoint - Hemostemix Inc. has received approval from the TSX Venture Exchange for a debt settlement involving the issuance of common shares at a price of $0.20 per share to settle CDN$400,000 of indebtedness [1][2][3] Group 1: Debt Settlement Details - The company will issue a total of 2,000,000 common shares to certain creditors at a deemed price of $0.20 per share [2] - The shares will be subject to a statutory hold period of four months and one day, in accordance with applicable securities laws [2] - The debt settlement is subject to acceptance by the TSX Venture Exchange and will not create a new control person [3] Group 2: Company Overview - Hemostemix is a leading autologous stem cell therapy company, founded in 2003, specializing in VesCell™ (ACP-01) for various cardiovascular diseases [1][4] - The company has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed publications [4] - Recent studies indicate that ACP-01 is safe and effective, showing a 0% mortality rate in chronic limb threatening ischemia patients, compared to a 50% mortality rate over five years in the general patient population [4]